Immunome Inc. Files 8-K Report

TL;DR

Immunome filed an 8-K on Jan 30th for Jan 29th events. Check for material updates.

AI Summary

Immunome Inc. filed an 8-K report on January 30, 2025, detailing events that occurred on January 29, 2025. The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'. The company is incorporated in Delaware and its principal executive offices are located in Bothell, WA.

Why It Matters

This 8-K filing indicates that Immunome Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — This is a routine SEC filing (8-K) that typically reports significant events, but the filing itself doesn't inherently present a new risk.

Key Players & Entities

• Immunome Inc. (company) — Registrant
• January 29, 2025 (date) — Earliest event reported
• January 30, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Bothell, WA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
• $7.75 — price to the public in the offering was $7.75 per share. All of the shares of Common
• $150.0 m — o the Company from the offering will be $150.0 million, before deducting underwriting di

Filing Documents

• tm254657d4_8k.htm (8-K) — 34KB
• tm254657d4_ex1-1.htm (EX-1.1) — 255KB
• tm254657d4_ex5-1.htm (EX-5.1) — 9KB
• tm254657d4_ex99-1.htm (EX-99.1) — 10KB
• tm254657d4_ex99-2.htm (EX-99.2) — 10KB
• tm254657d4_ex5-1img001.jpg (GRAPHIC) — 3KB
• tm254657d4_ex99-1img001.jpg (GRAPHIC) — 3KB
• tm254657d4_ex99-2img001.jpg (GRAPHIC) — 3KB
• 0001104659-25-007610.txt ( ) — 577KB
• immu-20250129.xsd (EX-101.SCH) — 3KB
• immu-20250129_lab.xml (EX-101.LAB) — 33KB
• immu-20250129_pre.xml (EX-101.PRE) — 22KB
• tm254657d4_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. Follow-On Public Offering On January 29, 2025, Immunome, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale in a public offering of 19,354,839 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). The price to the public in the offering was $7.75 per share. All of the shares of Common Stock are being sold by the Company. The gross proceeds to the Company from the offering will be $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The closing of the offering is expected to occur on January 31, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to 2,903,225 additional shares of Common Stock at the public offering price, less the underwriting discounts and commissions. The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by such parties. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-277036) that was filed with the U.S. Securities and Exchange Commissio

Forward Looking Statements

Forward Looking Statements Certain statements contained in this report regarding the Company's expectations regarding the offering are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the Company's expectations regarding the market conditions, the satisfaction of customary closing conditions related to the offering and the Company's ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. All forward-looking statements contained in this report speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1

Underwriting

Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Cowen and Company, LLC, Leerink Partners LLC, and Guggenheim Securities, LLC, dated January 29, 2025. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 99.1 Press Release, dated January 29, 2025. 99.2 Press Release, dated January 29, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Immunome, Inc. Dated: January 30, 2025 By: /s/ Clay Siegall Clay Siegall, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR